Transplant Biomarker Risk Stratification Market : Global Industry Analysis and Opportunity Assessment, 2036

Future Market Insights

Transplant Biomarker Risk Stratification Market

Key Insight

Donor-derived cell-free DNA accounts for 35.3% of the transplant biomarker risk stratification market by biomarker type. Acute rejection risk assessment leads the application category with 33.9%. Both segments reflect growing use of molecular evidence to support graft monitoring, biopsy decisions, and treatment review.

July 30, 2026

Anurag Sharma

250 Pages

Cite this Report

Transplant Biomarker Risk Stratification Market

https://www.futuremarketinsights.com/reports/transplant-biomarker-risk-stratification-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

CareDx
Natera
Verici Dx
Insight Molecular Diagnostics
Eurofins Viracor
Thermo Fisher Scientific
Omixon
Werfen

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Transplant Biomarker Risk Stratification Market

Key Players

Similar Industry Reports